Clinical studies have indicated that human leukocyte antigen (HLA)-DPB1 functions as a classical transplantation antigen in allogeneic stem cell transplantation (SCT). Mismatching for HLA-DPB1 was associated with an increased risk of graft-versus-host disease (GVHD) but also a decreased risk of disease relapse. 1, 2 However, some studies showed that specific HLA-DPB1 mismatches were associated with poor clinical outcome. 3 It was suggested that this unfavorable effect was caused by differences in immunogenicity between HLA-DPB1 alleles. An algorithm defining permissive and nonpermissive HLA-DPB1 mismatches was developed based on cross-reactive T-cell reactivity patterns. It was suggested that permissive mismatches would not result in T-cell ISM indicates indolent systemic mastocytosis (SM); SSM, smoldering SM; BMM, isolated bone marrow mastocytosis; BM, bone marrow; MC, mast cell; LNP, lymphadenopathy; PG, prostaglandin; UNL, upper normal limit; Cr, creatinine; NS, not significant; n/a, not applicable; and -, unknown or not done. SSM is defined by the presence of 2 or more "B-findings" (ie, BM MC Ͼ 30% or serum tryptase Ͼ 200 ng/mL, BM hypercellularity or dysmyelopoiesis without cytopenias, and organomegaly and/or lymphadenopathy without functional impairment). Causes of death were available for 14 of the 26 deaths: disease transformation (n ϭ 4; all SSM), cardiovascular (n ϭ 3; all ISMo), solid tumor (n ϭ 4; 3 ISMo and 1 BMM), complications of MC mediator release (n ϭ 2; 1 each SSM and ISMo), and infection (n ϭ 1; SSM 
